Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Favipiravir, Lopinavir/Ritonavir or Combination Therapy: a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19

NCT04499677 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT04499677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04499677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Favipiravir, Lopinavir/Ritonavir or Combination Therapy: a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Completed
Start date
September 24, 2020
Completion date
January 17, 2022
Enrollment
240 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19